drugset / Trial / NCT00088582

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

NCT00088582

Phase 2 Completed 62 enrolled Novartis Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.

Timeline

Start
2004-03
Primary completion
2005-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 100 ug Subcutaneous
Subject Pasireotide Other / unclassified 200 ug Subcutaneous
Subject Pasireotide Other / unclassified 400 ug Subcutaneous
Subject Pasireotide Other / unclassified 600 ug Subcutaneous

Indications